Atorvastatin in combination with ezetimibe and carotid atherosclerosis

Genetics and Molecular Research

Volumn 13, Issue 3, 2014, Pages 4805-4807

  Paraskevas, K I ^a   Mikhailidis, D P ^b   Giannoukas, A D ^c  

^a NORTHERN GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY HOSPITAL OF LARISSA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL; AZETIDINE DERIVATIVE; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

ARTERIAL WALL THICKNESS; CARDIOVASCULAR RESPONSE; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; HUMAN; LETTER; PROTEIN BLOOD LEVEL; RISK REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; CAROTID ARTERY DISEASES; FEMALE; HYPERCHOLESTEROLEMIA; MALE;

AZETIDINES; CAROTID ARTERY DISEASES; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; MALE; PYRROLES;

EID: 84904012003     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2014.July.2.10     Document Type: Letter

References (19)

1. Anderson TJ, Grégoire J, Hegele RA, Couture P, et al. (2013). 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can. J. Cardiol. 29: 151-167.
2. Catapano AL, Reiner Z, De Backer G, Graham I, et al. (2011). ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 217 (Suppl 1): S1-44.
3. Fras Z and Mikhailidis DP (2008). Statin plus ezetimibe treatment in clinical practice: the SI-SPECT (Slovenia (SI) Statin Plus Ezetimibe in Cholesterol Treatment) monitoring of clinical practice study. Curr. Med. Res. Opin. 24: 2467-2476.
4. Gazi IF, Daskalopoulou SS, Nair DR and Mikhailidis DP (2007). Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Curr. Med. Res. Opin. 23: 2183-2192.
5. Gouni-Berthold I, Mikhailidis DP and Rizzo M (2012). Clinical benefits of ezetimibe use: is absence of proof, proof of absence? Expert. Opin. Pharmacother. 13: 1985-1988.
6. IAS Position Paper (2014). Global Recommendations for the Management of Dyslipidaemia. Available at [http://www.athero.org/IASPositionPaper.asp]. Accessed 18 April 2014.
7. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, et al. (2008). Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med. 358: 1431-1443.
8. Lioudaki E, Ganotakis ES and Mikhailidis DP (2011). Ezetimibe; more than a low density lipoprotein cholesterol lowering drug? An update after 4 years. Curr. Vasc. Pharmacol. 9: 62-86.
9. Luo P, Li L, Wang LX, Zhu HH, et al. (2014). Effects of atorvastatin in combination with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia. Genet. Mol. Res. 13: 2377-2384.
10. Migdalis I, Efthimiadis A, Pappas S, Alexopoulos D, et al. (2009). Clinical experience with ezetimibe/simvastatin in a Mediterranean population. Curr. Med. Res. Opin. 25: 2571-2576.
11. Mikhailidis DP, Sibbring GC, Ballantyne CM, Davies GM, et al. (2007). Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr. Med. Res. Opin. 23: 2009-2026.
12. Mikhailidis DP, Lawson RW, McCormick AL, Sibbring GC, et al. (2011). Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis. Curr. Med. Res. Opin. 27: 1191-1210.
13. Mikhailidis DP and Athyros VG (2014). Dyslipidaemia in 2013: New statin guidelines and promising novel therapeutics. Nat. Rev. Cardiol. 11: 72-74.
14. Paraskevas KI, Veith FJ and Mikhailidis DP (2011). Carotid intima-media thickness and ezetimibe: the end of a misunderstanding? Curr. Vasc. Pharmacol. 9: 381-384.
15. Perk J, De Backer G, Gohlke H, Graham I, et al. (2012). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur. Heart J. 33: 1635-1701.
16. Shigematsu E, Yamakawa T, Taguri M, Morita S, et al. (2012). Efficacy of ezetimibe is associated with gender and baseline lipid levels in patients with type 2 diabetes. J. Atheroscler. Thromb. 19: 846-853.
17. Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, et al. (2013). 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol.
18. Teramoto T, Sasaki J, Ishibashi S, Birou S, et al. (2013). Comprehensive risk management for the prevention of cardiovascular disease: executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan-2012. J. Atheroscler. Thromb. 20: 603-615.
19. Wanner C and Tonelli M (2014). KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int. 85: 1303-1309.